



NCRI

National
Cancer
Research
Institute

cancer c■nference
ncri
national cancer research institute

CONFERENCE PROGRAMME

2007 NCRI Cancer Conference, 30 September - 3 October 2007, The ICC, Birmingham, UK

Programme Contents

Programme at a Glance **3**

Symposia **7**

For the first time, the Conference features a number of symposia on subjects of broad appeal, including: 25 years of Ras; Clinical trials in an environment of new agents; and Biomarkers for cancer predisposition screening and prognosis.

Parallel Sessions **10**

This year's sessions cover a breadth of topics, based on the central themes of cancer cell biology, clinical research, enabling infrastructure and resources, epidemiology and prevention, patients and the public, supportive and palliative care, and therapeutic development.

Workshops **27**

The Conference also features workshops designed for specialists involved in cancer research, addressing subjects such as careers and development, clinical trial design, and issues affecting women in science.

Programme at a Glance

Sunday 30 September 2007

12.30 – 13.45

AstraZeneca Science Symposium - Patient selection strategies in oncology: opportunities and challenges



13.00 – 15.00

Workshops

14.00 – 15.00

Drug hunting to beat cancer: Public Seminar and Open Forum

Roger Griffin

Northern Institute for Cancer Research, Newcastle University, UK

15.15 – 15.30

Welcome address

Mike Richards

NCRI Chairman

15.30 – 16.10

Mouse models for cancer - The Beatson Institute for Cancer Research Lecture

Anton Berns

Netherlands Cancer Institute, The Netherlands



16.10 – 16.50

Promoting early presentation with cancer - The Economic and Social Research Council Lecture

Amanda Ramirez

King's College London, UK



16.50 – 17.20

Refreshment Break

17.20 – 18.00

Sensing of infection and anti-tumour immunity – The AstraZeneca Lecture

Caetano Reis e Sousa

CR-UK London Research Institute, UK



18.00 – 18.40

Targeting epigenetic alterations in breast cancer - The CR-UK Cambridge Research Institute Lecture

Nancy Davidson

Johns Hopkins University School of Medicine, Baltimore, USA



19.00 – 21.00 Civic Opening Reception and Trade Exhibition

Monday 1 October 2007

08.00 – 08.50 Educational Workshops

09.00 – 09.10 **Introduction to the programme**
Alan Ashworth
Programme Planning Committee Chairman

09.10 – 09.50 **Drugging the ‘undruggable’ - The CR-UK London Research Institute Lecture**
Gregory Verdine
Harvard University, Cambridge, USA



09.50 – 10.30 **Immunological checkpoint blockade in cancer therapy – The Leukaemia Research Fund Lecture**
James Allison
Memorial Sloan-Kettering Cancer Center, New York, USA



10.30 – 11.00 Refreshment Break and Exhibition Viewing

11.00 – 12.30 Symposia

12.30 – 15.00 Lunch, Poster Session 1 and Trade Exhibition

13.00 – 14.00 Commercial Workshops

14.00 – 15.00 Workshops

15.15 – 17.30 Parallel Sessions

17.30 – 18.00 Refreshment Break

18.00 – 19.00 **Clinical Trials Showcase**

19.20 – 21.00 Drinks Reception

19.20 – 20.30 Sponsors' Reception (by invitation only)

20.30 – 23.00 Chairman's Dinner (by invitation only)

Tuesday 2 October 2007

08.00 – 08.50

Educational workshops

09.00 – 09.40

Pancreatic cancer models and medicine – The Cancer Research UK Lecture

David Tuveson

CR-UK Cambridge Research Institute, UK

CANCER RESEARCH UK



09.40 – 10.20

Living beyond cancer: the challenges of survivorship care – The Cancer Research UK Lecture

Mary McCabe

Memorial Sloan-Kettering Cancer Center, New York, USA

CANCER RESEARCH UK



10.20 – 11.00

Refreshment Break and Exhibition Viewing

11.00 – 12.30

Symposia

12.30 – 15.00

Lunch, Poster Session 2 and Trade Exhibition

13.00 – 14.00

Commercial Workshops

14.00 – 15.00

Workshops

15.15 – 17.30

Parallel Sessions

17.30 – 18.00

Refreshment Break

18.00 – 18.40

Nutritional and molecular markers in cancer prevention - The Medical Research Council Lecture

Sheila Bingham

MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, University of Cambridge, UK

MRC

Medical
Research
Council

18.40 – 19.20

Using cancer genomics to inform targeted drug development - The Medical Research Council Lecture

MRC

Medical
Research
Council

Barbara Weber
GlaxoSmithKline, USA

20.00 – 20.30

Drinks Reception

20.30 – 02.00

Conference Dinner and Party

Wednesday 3 October

09.00 – 11.15

Parallel Sessions

11.15 – 11.45

Refreshment Break

11.45 – 12.25

**Future prospects for targeted therapies -
The BACR Tom Connors Lecture**



Frank McCormick

University of California, Comprehensive Cancer Center, San Francisco, USA

12.25 – 12.35

Closing Comments

Mike Richards

NCRI Chairman

12.35 – 13.30

Lunch Boxes

13.00 – 17.30

Commercial Workshop

Symposia

Monday 1 October 2007

25 years of Ras – Sponsored by The Institute of Cancer Research

Hosted by Chris Marshall

The Institute of Cancer Research, London, UK

- **Chris Marshall**
The Institute of Cancer Research, London, UK
Introduction: Ras oncogenes - what next?
- **John Hancock**
Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
Spatiotemporal control of Ras plasma membrane signalling
- **Judith Sebolt-Leopold**
JS Leopold Consulting, Michigan, USA
MEK inhibitors: a personalised medicine approach for targeting aberrant MAP kinase signalling
- **Julian Downward**
CR-UK London Research Institute, UK
The Ras oncogene signalling network in cancer



Clinical trials in an environment of new agents - Sponsored by the Paterson Institute for Cancer Research and the Manchester Cancer Research Centre

Hosted by Stan Kaye

The Institute of Cancer Research and Royal Marsden Hospital, London, UK

- **Stan Kaye**
The Institute of Cancer Research and Royal Marsden Hospital, London, UK
Introduction: novel agents for treating cancer; how has the landscape changed?
- **Mitch Dowsett**
The Institute of Cancer Research and Royal Marsden Hospital, London, UK
Opportunities and limitations of short-term clinico-biological studies
- **Jaap Verweij**
Erasmus University Medical Center, Rotterdam, The Netherlands
How to assess response – changing concepts about endpoints
- **Mark Ratain**
Cancer Research Center, University of Chicago, USA
How to assess response – is randomisation necessary?



Complementary therapies

Hosted by Andrew Ritchie

Papworth Hospital, Cambridge, UK

- **Andrew Ritchie**
Papworth Hospital, Cambridge, UK
Introduction
- **Edzard Ernst**
Peninsula Medical School, Exeter, UK
CAM for cancer: the good, the bad and the ugly
- **George Lewith**
Peninsula Medical School, Exeter, UK
CAM and cancer: what do we know and how do we move forward?
- **Donald Sharp**
Institute of Rehabilitation, University of Hull, UK
Prevention – the impact of lifestyle factors

Tuesday 2 October 2007

Biomarkers for cancer predisposition, screening and prognosis – Sponsored by Illumina

Hosted by Herbie Newell

Northern Institute for Cancer Research, Newcastle University, UK

- **Herbie Newell**
Northern Institute for Cancer Research, Newcastle University, UK
Introduction: predisposition, screening and prognostic biomarkers in cancer management
- **Paul Pharoah**
Strangeways Research Laboratory, University of Cambridge, UK
Genome-wide association studies for common cancer-predisposing genes
- **Fritz Schröder**
Erasmus Medical Centre, Rotterdam, The Netherlands
Early detection of prostate cancer in 2007
- **Ian Smith**
The Institute of Cancer Research and Royal Marsden Hospital, London, UK
Prognostic and predictive biomarkers in early breast cancer



Chromatin regulation and cancer

Hosted by Tony Kouzarides

The Wellcome Trust/CR-UK Gurdon Institute, University of Cambridge, UK

- **Tony Kouzarides**
Wellcome Trust/CR-UK Gurdon Institute, University of Cambridge, UK
Introduction: chromatin modifications, pathways and cancer
- **Steve Baylin**

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Baltimore, USA

The gene silencing component of the cancer epigenome

- **Kristian Helin**

Biotech Research and Innovation Centre, University of Copenhagen,
Denmark

Epigenetic control and the development of cancer

- **Manel Esteller**

Spanish National Cancer Centre, Madrid, Spain

DNA methylation and cancer

- **Pier Giuseppe Pelicci**

European Institute of Oncology, Milan, Italy

**Higher-order chromatin changes induced by an oncogenic
transcription factor**

Prevention

Hosted by **William Steward**

Leicester Royal Infirmary, University of Leicester, UK

- **William Steward**

Leicester Royal Infirmary, University of Leicester, UK

**Introduction: cancer prevention strategies – importance for the
future management of the burden of cancer in society**

- **Julian Peto**

The Institute of Cancer Research and the London School of Hygiene and
Tropical Medicine, UK

Prevention – the impact of lifestyle factors

- **Andrea Decensi**

Ente Ospedaliero Ospedali Galliera, Genoa, Italy

Clinical chemoprevention: where do we stand?

- **Andreas Gescher**

University of Leicester, UK

Cancer prevention – the way ahead

Parallel Sessions

Monday 1 October 2007

Angiogenesis - Sponsored by AstraZeneca

Hosted by Roy Bicknell

Institute for Biomedical Research, University of Birmingham, UK

- **Roy Bicknell**
Institute for Biomedical Research, University of Birmingham, UK
Introduction: Robo4 in endothelial biology and angiogenesis
- **Holger Gerhardt**
CR-UK London Research Institute, UK
Regulating sprouting angiogenesis
- **Andreas Bikfalvi**
Inserm, University of Bordeaux I, Talence, France
New insights into the regulation of tumour angiogenesis: mechanisms, models and molecules
- **Stephen Wedge**
AstraZeneca, Macclesfield, UK
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors: potential and recent clinical progress
- **Richard Sainson**
University of Oxford, UK
In vivo assessment of Delta like-4 function in tumour development – Proffered Paper Presentation
- **Francois Pepin**
McGill University, Montreal, Quebec, Canada
Identification and characterisation of classes of endothelial gene expression in breast cancer – Proffered Paper Presentation
- **Russell Hughes**
University of Sheffield Tumour Targeting Group, South Yorkshire, UK
Use of a transgenic zebrafish embryo to investigate the anti-angiogenic and anti-vascular effects of a novel pentapeptide derived from human fibronectin – Proffered Paper Presentation



Breast cancer stem cells and detection of minimal residual disease – Sponsored by GlaxoSmithKline

Hosted by Rob Coleman

Weston Park Hospital, University of Sheffield, UK

- **Rob Coleman**
Weston Park Hospital, University of Sheffield, UK
Introduction: how can we rationalise the treatment of micrometastatic disease?
- **Robert Clarke**
Department of Medical Oncology, University of Manchester, UK



- Regulation of human breast cancer stem cells
- **Sabine Riethdorf**
Institute for Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Detection and characterisation of circulating tumour cells in blood and micrometastasis in bone marrow
- **Charles Coombes**
Hammersmith Hospital, London, UK
Minimal residual disease in patients with primary breast cancer: role in monitoring patients
- **Paul Symonds**
University of Leicester, UK
The late radiotherapy normal tissue phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependant causes – Proffered Paper Presentation
- **Andrew Green**
University of Nottingham, UK
Identification of breast cancer sub-classes by consensus derived from automated clustering methods – Proffered Paper Presentation
- **Heiko Enderling**
Tufts University, Boston, USA
A mathematical model of breast cancer development, local treatment and recurrence – Proffered Paper Presentation

Cancer epidemiology

Hosted by Peter Sasieni

Wolfson Institute of Preventive Medicine, Queen Mary's School of Medicine and Dentistry, UK

- **Peter Sasieni**
Wolfson Institute of Preventive Medicine, Queen Mary's School of Medicine and Dentistry, UK
Introduction
- **Gad Rennert**
Carmel Medical Center and B Rappaport Faculty of Medicine, Technion, Israel
Colorectal cancer prevention: health habits, use of medications and genes
- **Maxwell Parkin**
University of Oxford, UK
Epidemiology of breast cancer: how much can we prevent?
- **Rowan Chlebowski**
Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, California, USA
The Women's Health Initiative randomised trials of menopausal hormone therapy
- **Tim Key**
University of Oxford, UK
Diet, hormones and prostate cancer: findings in the EPIC study – Proffered Paper Presentation

- **Gerhardt Attard**
The Institute of Cancer Research, Sutton, UK
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer – Proffered Paper Presentation
- **John Burn**
Newcastle University, UK
The CAPP2 chemoprevention study of bowel neoplasia among persons with hereditary non-polyposis colorectal cancer – Proffered Paper Presentation

Colorectal cancer - Sponsored by The Bobby Moore Fund

Hosted by John Northover

St Mark's Hospital, Middlesex, UK



- **John Northover**
St Mark's Hospital, Middlesex, UK
Introduction
- **Wendy Atkin**
St Mark's Hospital, Imperial College London, UK
NHS population screening: possible developments in the next five years
- **Paul Finan**
Leeds General Infirmary, UK
Abdominoperineal excision of rectum (APER) - a suitable case for treatment
- **Tom Treasure**
Guy's Hospital, London, UK
Pulmonary metastasectomy: its role should be better defined
- **Helen Thorpe**
University of Leeds, UK
CLASICC Trial (Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer): 5-year survival results – Proffered Paper Presentation
- **S Paneesha**
Heart of England NHS Trust, Birmingham, UK
Venous thrombosis has an adverse impact on the survival in patients with malignancy – Proffered Paper Presentation
- **Trevor McGoldrick**
University of Edinburgh, Scotland, UK
National survey of fluoropyrimidine induced cardiac ischaemia – Proffered Paper Presentation

Molecular pathology - Sponsored by the Pathological Society of Great Britain and Ireland

Hosted by Nick Lemoine

Institute of Cancer and CR-UK Clinical Centre, University of London, UK



- **Nick Lemoine**
Institute of Cancer and CR-UK Clinical Centre, University of London, UK

Introduction: what do we need to qualify biomarkers in molecular pathology?

- **Paul Waring**
Genentech, San Francisco, USA
The importance of selecting the right patients for the right drugs
- **Heike Grabsch**
University of Leeds, UK
Molecular profiling of gastrointestinal malignancies for targeted therapy
- **Nils Brunner**
Copenhagen University Hospital, Denmark
Cancer biomarkers in a European perspective
- **Emma Dean**
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
Cell death ELISAs in the clinical evaluation of AEG35156 (XIAP Antisense): a multifaceted biomarker? – Proffered Paper Presentation
- **Muireann Kelleher**
Randall Division and Cancer Studies, King's College London, UK
High throughput optical proteomics and breast cancer patient profiling; novel applications to individualise prognosis and treatment – Proffered Paper Presentation
- **Loreta Rodrigues**
CR-UK Cambridge Research Institute, UK
Pharmacodynamic markers in *C-neu*/HER2 overexpressing mammary carcinomas in response to 17-AAG measured by ³¹P magnetic resonance spectroscopy – Proffered Paper Presentation

Signalling pathways

Hosted by Xin Lu

Ludwig Institute for Cancer Research, UK

- **Xin Lu**
Ludwig Institute for Cancer Research, UK
Introduction
- **Carl-Henrik Heldin**
Ludwig Institute for Cancer Research, Uppsala University, Sweden
Signal transduction via receptors for PDGF and TGF- β : possible targets in tumour therapy
- **George D Demetri**
Dana-Farber Cancer Institute, Boston, USA
Molecular therapeutics targeting aberrant kinase signalling in gastrointestinal stromal tumours (GIST): lessons for rational drug design and pathway-focused clinical development
- **Stefan Constantinescu**
Ludwig Institute for Cancer Research, Brussels, Belgium
Signalling by JAK2 V617F and thrombopoietin receptor mutants in human myeloproliferative diseases

- **Surbhi Gupta**
CR-UK London Research Institute, UK
The interaction of Ras with p110 α is required for Ras-driven tumorigenesis and for normal lymphatic development – Proffered Paper Presentation
- **Adrian Saurin**
CR-UK London Research Institute, UK
The regulated assembly of a PKC epsilon complex controls the completion of cytokinesis – Proffered Paper Presentation
- **Ivana Samarzija**
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Studies on Memo, a novel ERBB2 effector protein – Proffered Paper Presentation

Survival strategies and clinical trials

Hosted by Roger Wilson

NCRI Consumer Liaison Group, UK

- **Roger Wilson**
NCRI Consumer Liaison Group, UK
Introduction
- **Jan Geissler**
European Cancer Patient Coalition, Germany
Cancer trials as live savers: a patient's perspective on public trial information
- **Ian Judson**
Royal Marsden Hospital, London, UK
Early clinical trials in cancer – human toxicology studies or realistic hope of benefit?
- **Derryn Borley**
Cancerbackup, UK
The role of patient support and information services
- **Donald Sharp**
University of Hull, UK
Integrated psychosocial support services for people with cancer enhance equity of use – Proffered Paper Presentation

Symptom management

Hosted by Michael Sharpe

Edinburgh Cancer Research Centre, University of Edinburgh, UK

- **Michael Sharpe**
Edinburgh Cancer Research Centre, University of Edinburgh, UK
Introduction: improving the management of symptoms in people with cancer - trials and tribulations
- **Michael Sharpe**
Edinburgh Cancer Research Centre, University of Edinburgh, UK
A randomised trial of a multi-component intervention for major depressive disorder in cancer patients
- **Gijs Bleijenberg**

Radboud University, Nijmegen Medical Centre, The Netherlands
A randomised trial of cognitive behaviour therapy for fatigue in cancer survivors

- **Matthew Hotopf**

Institute of Psychiatry, Weston Education Centre, London, UK

Integrating principles of cognitive behavioural therapy in palliative care: a cluster randomised trial of nurse training

- **Jo Armes**

King's College London, UK

A randomised controlled trial to evaluate the effectiveness of a brief behaviourally oriented intervention for cancer-related fatigue – Proffered Paper Presentation

- **Moyra Mills**

Queen's University Belfast, Northern Ireland, UK

A randomised controlled trial of a patient-held quality of life diary for patients with inoperable lung cancer – Proffered Paper Presentation

- **Galina Velikova**

Cancer Research UK Centre, Leeds, UK

Patients' and doctors' attitude to the routine use of quality of life assessment in oncology practice – Proffered Paper Presentation

Tuesday 2 October 2007

Biobanking

Hosted by Gerry Thomas

Hammersmith Hospital, London, and Wales Cancer Bank, Cardiff, UK

- **Gerry Thomas**

Hammersmith Hospital, London, and Wales Cancer Bank, Cardiff, UK

Introduction

- **Lisa Devereux**

Peter MacCallum Cancer Centre, Melbourne, Australia

The Australasian Biospecimen Network (ABN): progress so far. A tale of linkage, supply and co-operation

- **Fay Betsou**

Responsable Laboratoire, Saleux, France

Biobanks in France and the Biobanque de Picardie paradigm

- **Chris Womack**

AstraZeneca, UK

What industry wants from cancer research tissue banks – ethics, quality and data

- **Susan Bray**

University of Dundee, Scotland, UK

Colorectal cancer gene expression profiles are dependent upon tissue ischaemic time and tissue handling protocols – Proffered Paper Presentation

- **Gavin Whyman**
Children's Cancer and Leukaemia Group, University of Leicester, UK
The childhood tumour and leukaemia banks - A national protocol for collecting and banking childhood cancer tissue samples for research – Proffered Paper Presentation
- **Rebecca Elliott**
University of Manchester, UK
VORTEX-BIOBANK: Translational tissue banking study – Proffered Paper Presentation

Cervical cancer vaccines - Sponsored by Merck Sharp & Dohme

Hosted by Henry Kitchener
University of Manchester, UK



- **Henry Kitchener**
University of Manchester, UK
Introduction: the role of prophylactic human papillomavirus vaccination
- **Richard Roden**
Johns Hopkins School of Medicine, Baltimore, USA
Second generation human papillomavirus vaccines based on L2
- **Cornelius Melief**
Leiden University Medical Centre, The Netherlands
Long peptide vaccine-induced migration of HPV16 specific type 1 and 2 T cells into the lesions of VIN III patients, associated with complete clinical responses
- **Loretta Brabin**
University of Manchester, UK
Human papillomavirus vaccine implementation issues
- **Neil Steven**
University of Birmingham, UK
Vaccination of patients with Epstein-Barr virus positive malignancy with modified Vaccinia Ankara expressing a chimaeric EBV EBNA 1 and LMP2 antigen – Proffered Paper Presentation
- **Robin Prestwich**
CR-UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds, UK
Reovirus infection of human melanoma cells supports priming of anti-tumour cytotoxic T cell immunity – Proffered Paper Presentation
- **Robin Prestwich**
CR-UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds, UK
Clinical study of intralymphatic delivery of OK432-matured dendritic cells for activation of innate anti-tumour immunity – Proffered Paper Presentation

Exercise, the mind and curative intent

Hosted by Nina Ennis

NCRI Consumer Liaison Group, UK

- **Nina Ennis**
NCRI Consumer Liaison Group, UK
Introduction
- **Donald Sharp**
Institute of Rehabilitation, University of Hull, UK
Integrating the researcher, the clinician and the patient in psycho-oncology research: pleasing all of the people all of the time?
- **Amanda Daley**
University of Birmingham, UK
Rest is not best: exercise therapy and quality of life in women treated for breast cancer
- **Francis Creed**
School of Medicine, University of Manchester, UK
Can a brief psychological intervention prevent affective disorders in cancer patients? A randomised controlled trial
- **Susan Palmer**
Thames Valley Cancer Research Network, Oxford, UK
Does increasing research awareness impact on accrual? A feasibility study (NCRN Portfolio: RAW study) – Proffered Paper Presentation

High-throughput siRNA screening

Hosted by Julian Downward

CR-UK London Research Institute, UK

- **Julian Downward**
CR-UK London Research Institute, UK
Introduction: high throughput RNA interference in the analysis of signalling pathways involved in oncogenic transformation
- **Michael White**
University of Texas Southwestern Medical Center, Dallas, USA
Harnessing genome-wide RNAi to guide rational design of combinatorial chemotherapies
- **Christoph Sachse**
Cenix BioScience GmbH, Dresden, Germany
Combining high throughput RNAi with high content assays to advance anti-cancer drug discovery and development
- **Andrew Fraser**
Wellcome Trust Sanger Institute, Cambridge, UK
Learning from the worm: predicting phenotype from genotype
- **Lindsay Stimson**
University of Oxford, UK
Genome-wide loss-of-function screen reveals an unexpected mechanism for HDAC-inhibitor-induced apoptosis – Proffered Paper Presentation
- **Michael Steckel**

CR-UK London Research Institute, UK
Probing Ras signalling: an activated oncogene “synthetic lethal” screen – Proffered Paper Presentation

Integration of new molecular therapies with radiation – Sponsored by The Royal College of Radiologists and The British Oncological Association

Hosted by Chris Nutting and Frances Calman

Royal Marsden Hospital, London, UK and The Royal College of Radiologists,
London, UK



- **Chris Nutting and Frances Calman**
Royal Marsden Hospital, London, UK and The Royal College of Radiologists, London, UK
Introduction
- **Chris Boshoff**
Wolfson Institute for Biomedical Research, University College London, UK
Novel molecular targets and molecules in cancer therapy
- **Suresh Senan**
VU University Medical Center, Amsterdam, The Netherlands
Epidermal growth factor modulation and vascular targeted agents combined with radiation therapy: early lessons from clinical trials
- **Kevin Harrington**
The Institute of Cancer Research, London, UK
Biological approaches to radiosensitisation: viruses, gene therapy and novel radiosensitisers
- **Fadhel Shaheen**
Northern Institute for Cancer Research, Newcastle Upon Tyne, UK
Targeting the DNA repair machinery to develop novel therapies for prostate cancer – Proffered Paper Presentation
- **Judith Anderton**
AstraZeneca, Macclesfield, United Kingdom
Preclinical studies comparing the pharmacological profiles of the EGFR tyrosine kinase inhibitors gefitinib (IRESSA™) and erlotinib (Tarceva™) – Proffered Paper Presentation
- **Samra Khan**
Northern Institute of Cancer Research, Newcastle upon Tyne, UK
DNA damage and repair in *BRCA2* heterozygotes in response to ionising radiation and PARP inhibitors – Proffered Paper Presentation

Living with cancer as a chronic illness

Hosted by Karen Luker

School of Nursing, University of Manchester, UK

- **Karen Luker**
School of Nursing, University of Manchester, UK
Introduction
- **Noreen Aziz**

Division of Cancer Control and Population Sciences,
National Cancer Institute, USA

Cancer as a chronic illness: overcoming adverse sequelae to
achieve an optimal new normal

○ **Gerry Humphris**

University of St Andrews, Fife, Scotland, UK

Concerns for the future: cancer survivors' psychological
trajectory following treatment

○ **Carol Tishelman**

Karolinska Institute and Stockholms Sjukhem Foundation, Stockholm,
Sweden

Living with cancer as a chronic disease: accommodating user
perspectives and priorities to better alleviate problems and
support strengths

○ **Nada Khan**

University of Oxford, UK

Long-term cancer survivors in primary care: a systematic
review of uptake of services and support needs – Proffered
Paper Presentation

○ **Judith Mills**

The Institute of Cancer Research, Sutton, UK

Return to paid and unpaid activities after radiotherapy for early
stage breast cancer – Proffered Paper Presentation

○ **Claire Foster**

University of Southampton, UK

Psychosocial implications of long term survival following a
cancer diagnosis – Proffered Paper Presentation

**Paediatric cancers – Organised by the Children's Cancer
and Leukaemia Group, sponsored by Children with Leukaemia**

Hosted by Sue Burchill

CR-UK Clinical Centre, St James's University Hospital, Leeds, UK

○ **Sue Burchill**

CR-UK Clinical Centre, St James's University Hospital, Leeds, UK

Introduction: challenges for the implementation of biomarker-
based targeted therapy

○ **Julia Glade Bender**

Children's Hospital of New York-Presbyterian, Columbia University, USA

The development of VEGF targeted therapies in paediatric
solid tumours

○ **Vaskar Saha**

University of Manchester, UK

Novel therapeutic targets in childhood acute lymphoblastic
leukaemia

○ **Caroline Dive**

Paterson Institute for Cancer Research, University of Manchester, UK

Targeting death pathways for therapeutic advantage in
childhood malignancy

○ **Guy Makin**



University of Manchester, UK

Pre-clinical evaluation of the novel alkylating agent RH1 against paediatric tumour cell lines – Proffered Paper Presentation

- **Tapiwanashe Magwere**

University of Leeds, UK

Cellular glutathione modulates ESFT sensitivity to fenretinide-induced cell death – Proffered Paper Presentation

- **Sarah Holt**

Paterson Institute for Cancer Research, Manchester, UK

A novel XIAP antisense oligonucleotide induces apoptosis and sensitises paediatric tumour cells to cytotoxics – Proffered Paper Presentation

Structural biology

Hosted by Yvonne Jones

Wellcome Trust Centre for Human Genetics, Oxford, UK

- **Yvonne Jones**

Wellcome Trust Centre for Human Genetics, Oxford, UK

Introduction

- **David Barford**

The Institute of Cancer Research, London, UK

Structural and functional studies of argonaute proteins

- **Sir Alan Fersht**

MRC Centre for Protein Engineering, University of Cambridge, UK

The tumour suppressor p53: structure, function - rescue

- **Daan van Aalten**

University of Dundee, UK

Structural dissection of the LKB1 tumour suppressor complex

- **Brenda Kostelecky**

CR-UK London Research Institute, UK

PKC regulation and specificity: a study of novel isoforms – Proffered Paper Presentation

- **Heide Kogelberg**

Royal Free and University College Medical School, London, UK

Generation of a single-chain Fv with binding specificity for the integrin, $\alpha\beta6$, by rational structure based antibody engineering – a promising agent for cancer therapy – Proffered Paper Presentation

- **Celine Cano-Soumillac**

Northern Institute for Cancer Research, Newcastle upon Tyne, UK

Structure-activity relationships for inhibitors of DNA-dependent protein kinase – Proffered Paper Presentation

Wednesday 3 October 2007

Basic biology of lung cancer

Hosted by Tim Eisen

University of Cambridge, UK

- **Tim Eisen**
University of Cambridge, UK
Introduction: blue sky research in a smoky disease
- **Pamela Rabbitts**
Leeds Institute of Molecular Medicine, St James's University Hospital, UK
Genetic abnormalities in lung tumour progression
- **Elisabeth Brambilla**
University Hospital Albert Michallon, Grenoble, France
Molecular pathological correlates in lung cancer
- **Thomas d'Amato**
Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA
Chemotherapy resistance testing in non-small cell lung cancer – integration into clinical trials
- **Martin Muers**
Leeds General Infirmary, UK
A randomised phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: The Medical Research Council (MRC) / British Thoracic Society (BTS) MS01 trial – Proffered Paper Presentation
- **Marianne Nicolson**
Aberdeen Royal Hospitals Trust, UK
Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): The MRC LU22 / NVALT 2 / EORTC 08012 multi-centre randomised trial – Proffered Paper Presentation
- **Nadia Ashraf**
Gloucestershire Oncology Centre, Cheltenham General Hospital, UK
RECIST guidelines overestimate the volumetric response of locally advanced Non-Small Cell Lung Cancer (NSCLC) to chemotherapy – Proffered Paper Presentation

Bioinformatics for cancer research

Hosted by Robin Clark

NCRI Informatics Initiative, London, UK

- **Robin Clark**
NCRI Informatics Initiative, London, UK
Introduction
- **Phil Quirke**
St James's University Hospital, Leeds, UK
Integration of cancer imaging and pathology
- **Ken Buetow**
National Cancer Institute, Rockville, USA
Enabling the molecular medicine revolution through network-centric biomedicine

- **Helen Byrne**
University of Nottingham, UK
Colorectal cancer in silico: a multiscale theoretical
- **Elizabeth Ireland**
Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, UK
Has the Consolidated Standards of Reporting Trials (CONSORT) statement improved the publication quality of early breast cancer (EBC) randomised controlled trials (RCTs) in systemic treatment: a systematic review – Proffered Paper Presentation
- **Clare Peckitt**
The Institute of Cancer Research, Sutton, United Kingdom
Defining endpoints for recurrence in randomised controlled trials of systemic therapy for early breast cancer: a call for standardisation – Proffered Paper Presentation
- **Crispin Miller**
Paterson Institute for Cancer Research, University of Manchester, UK
Exploiting sample variability to enhance the analysis of microarray data – Proffered Paper Presentation

Cancer in developing countries

Hosted by Maxwell Parkin

University of Oxford, UK

- **Maxwell Parkin**
University of Oxford, UK
Introduction: cancer in developing countries
- **Cecilia Sepulveda**
World Health Organisation, Geneva, Switzerland
WHO strategies for cancer control in developing countries
- **Rengaswamy Sankaranarayanan**
International Agency for Research on Cancer, Lyon, France
Early diagnosis and screening in developing countries
- **Ian Magrath**
International Network for Cancer Treatment and Research, Institute Pasteur, Brussels, Belgium
Treatment of cancer in developing countries
- **Valerie McCormack**
London School of Hygiene and Tropical Medicine, UK
Breast density in White, Afro-Caribbean and South Asian women in the UK – Proffered Paper Presentation
- **Benjamart Warasiha**
School of Pharmacy, The Robert Gordon University, Aberdeen, UK
Comparative analysis of cytochrome P450 mRNA expression between human Caucasian and Afro-Caribbean breast cancer cell lines – Proffered Paper Presentation
- **Sunita Saxena**
Institute Of Pathology, Indian Council of Medical Research, New Delhi, India

Gene expression profile of esophageal cancer in North East India by cDNA microarray analysis – Proffered Paper Presentation

Cancer Research UK's Drug Development Office and the New Agents Committee – Sponsored by Cancer Research UK

Hosted by Stephen Shuttleworth

CR-UK Drug Development Office, London, UK

- **Kate Searle**
CR-UK Drug Development Office, London, UK
Drug development at Cancer Research UK: the Drug Development Office and the New Agents Committee - evaluation of new agents for early phase clinical trials
- **Sarah Lowndes**
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Phase I study of ATN-224 (choline tetrathiomolybdate) in metastatic cancer
- **Malcolm Ranson**
Christie Hospital, University of Manchester, UK
CR-UK Phase I trial of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7 or 3 days in patients with advanced refractory cancer
- **Shamim Kazmi-Stokes and Hayley Farmer**
CR-UK Drug Development Office, London, UK
Preclinical development and safety strategy for regulatory approval of a Phase I trial of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4
- **Paul Jones**
CR-UK Drug Development Office, London, UK
Non-clinical development activities at the CR-UK Drug Development Office
- **Caterina Macedo**
CR-UK Drug Development Office, London, UK
Pharmacovigilance in CR-UK's Drug Development Office
- **Stephen Shuttleworth**
CR-UK Drug Development Office, London, UK
Initiatives for implementation of new clinical programmes

End of life care

Hosted by Julia Addington-Hall

School of Nursing and Midwifery, University of Southampton, UK

- **Julia Addington-Hall**
School of Nursing and Midwifery, University of Southampton, UK
Introduction: predictors of place of death
- **Luc Deliens**
Vrije Universiteit, Brussels, Belgium and VU University Medical Center, Amsterdam, The Netherlands



Hospital deaths in six European countries: population-based cross national study of factors associated with dying in hospital

- **Barbara Gomes**
Weston Education Centre, King's College London, UK
Home death in cancer: associated factors, future issues?
- **Carol Thomas**
Institute for Health Research, Lancaster University, UK
What can qualitative data add to knowledge about place of cancer deaths?
- **Peter Madden**
Thames Cancer Registry, King's College, London, UK
Using maps, ranked bar charts and funnel plots to examine variation in place of death from cancer in London's Primary Care Trusts – Proffered Paper Presentation
- **Simon Waters**
Medical Oncology, St James' University Hospital, Leeds, UK
Patient mortality within thirty days of receiving systemic anti-cancer therapy: The Leeds experience – Proffered Paper Presentation
- **Jamie Young**
University of Dundee, Scotland, UK
In hospital deaths with and without a gastrointestinal cancer operation in Scotland over ten years – Proffered Paper Presentation

Inflammation in cancer

Hosted by Claire Lewis

University of Sheffield Medical School, UK

- **Claire Lewis**
University of Sheffield Medical School, UK
Introduction: the emerging role of inflammation in tumour progression
- **Michele de Palma**
Institute for Cancer Research and Treatment, Milan, Italy
Role of Tie2-expressing monocytes in cancer
- **Thorsten Hagemann**
Institute of Cancer and CR-UK Clinical Cancer Centre, Barts and The London, UK
'Re-educating' tumour-associated macrophages
- **Karin de Visser**
Netherlands Cancer Institute, The Netherlands
Crosstalk between adaptive and innate immunity enhances epithelial cancer development
- **Russell Hughes**
University of Sheffield Tumour Targeting Group, South Yorkshire, UK
Necrotic debris activates a pro-tumour phenotype in human macrophages: role of the cell surface receptors, SR-A and TLR-2 – Proffered Paper Presentation

- **Kellie Charles**
Institute of Cancer, London, UK
TNF- α antagonism inhibits inflammatory cytokine gene expression profile and NF- κ B activity in the tumour microenvironment of patients with advanced ovarian epithelial cancer – Proffered Paper Presentation
- **Daniel Palmer**
University of Birmingham, UK
CD40 ligand cancer immuno-gene therapy directly induces apoptosis in human carcinomas – Proffered Paper Presentation

Patients, research and involvement

Hosted by Roger Wilson and Nina Ennis

NCRI Consumer Liaison Group, UK

- **Nina Ennis**
NCRI Consumer Liaison Group, UK
Introduction
- **Neil Formstone**
Wales Cancer Bank, Royal College of Pathologists Lay Committee, and Macmillan Listening Study, UK
What is patient advocacy in research?
- **Raymond Strachan**
Ceco Palliative Care Group, NCRN Palliative Care Group, Macmillan Cancer Support Research Group, Scottish Executive Cancer Group, Scottish Intercollegiate Guidelines Network and North of Scotland Cancer Group, UK
Research in Scotland: a service users input
- **Jim Elliott**
Macmillan Cancer Support, UK
Title to be confirmed
- **Ikumi Okamoto**
University of Southampton, UK
Impact of cancer on everyday life: a systematic appraisal of the research evidence – Proffered Paper Presentation
- **Julie Evans**
University of Oxford, UK
Experiences of cancer on www.dipex.org: an award winning ‘innovative and humanistic’ resource – Proffered Paper Presentation

Prostate cancer

Hosted by Jonathan Shamash

St Bartholomew's Hospital, London, UK

- **Jonathan Shamash**
St Bartholomew's Hospital, London, UK
Introduction
- **Johann de Bono**

The Institute of Cancer Research and Royal Marsden Hospital, London, UK

Hormone refractory prostate cancer may frequently remain ligand driven: inhibition of CYP17 by abiraterone

- **Norman Maitland**

University of York, UK

Prostate cancer stem cells: new therapeutic targets?

- **William Isaacs**

Johns Hopkins University, Baltimore, USA

Molecular genetics of prostate cancer - challenges and opportunities

- **Alison Reid**

Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Sutton, UK

Abiraterone, an oral, selective, irreversible inhibitor of CYP450c17, inhibits androgen and oestrogen synthesis and has activity in post-docetaxel castration resistant prostate cancer – Proffered Paper Presentation

- **Gerhardt Attard**

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK

Inhibition of androgen synthesis by selective inhibition of CYP450c17 results in a high response rate in castration-resistant prostate cancer (CRPC) – Proffered Paper Presentation

- **Jacqueline Stockley**

Northern Institute for Cancer Research, Newcastle University, UK

Androgen ablation increases cellular resistance to taxane based chemotherapy in prostate cancer cells – Proffered Paper Presentation

Workshops

Sunday 30 September 2007

AstraZeneca Science Symposium - Patient selection strategies in oncology: opportunities and challenges

Sponsored by AstraZeneca

12.30 – 13.45

Hosted by Stephen Wedge

AstraZeneca, Cheshire, UK

- **Stephen Wedge**
AstraZeneca, Cheshire, UK
Introduction
- **Alan Barge**
AstraZeneca, Cheshire, UK
Learning from the inhibition of EGFR signalling
- **Paul Smith**
AstraZeneca, Cheshire, UK
Understanding tumour dependencies on MEK signalling
- **Mark O'Connor**
KuDOS Pharmaceuticals Limited, Cambridge, UK
Targeted therapy based on DNA repair inhibition



Molecular profiling in cancer

Sponsored by the Cancer Recognised Research Group in Northern Ireland

13.00 – 15.00

Hosted by Hendrik van den Berg and Charles Campbell

Queen's University Belfast, Northern Ireland, UK

- **Carlos Caldas**
Department of Oncology, University of Cambridge, UK
Genomic heterogeneity of breast cancer - biological and clinical implications
- **Wendy Allen**
Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK
Identification of predictive signatures of response to chemotherapy in metastatic colorectal cancer
- **Niamh O'Brien**
Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK
The identification of transcriptional targets of TBX2 and their role in breast cancer proliferation
- **Glenda McGonigle**
Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK
Identification of *HOXA6* as a novel candidate gene in AML



- **Seóna McErlean**
University of Ulster, Coleraine, Northern Ireland, UK
The pathway to breast cancer invasion

Thrombosis and malignancy workshop

13.00 – 15.00

Chaired by Mike Richards

National Cancer Research Institute, UK

- **Anita Thomas**
Derriford Hospital, Plymouth, UK
The scale of the problem
- **Ajay Kakkar**
Barts and The London, Queen Mary's School of Medicine and Dentistry, London, UK
Prophylaxis
- **Annie Young**
3 Counties Cancer Network, UK
Treatment
- **Anthony Maraveyas**
Postgraduate Medical Institute, University of Hull, UK
Current clinical trials: FRAGEM
- **Simon Noble**
Cardiff University, UK
Current clinical trials: FRAGMATIC
- **Ajay Kakkar**
Barts and The London, Queen Mary's School of Medicine and Dentistry, London, UK
Future clinical research

Monday 1 October 2007

BACR educational workshop: RNAi technologies

08.00 – 08.50

Hosted by William Gallagher

University College Dublin, Ireland

- **Michael White**
University of Texas Southwestern Medical Center, Dallas, USA
Discovery biology and RNAi



BOA educational workshop: Clinical application of cancer genetics

08.00 – 08.50

Hosted by Ros Eeles

The Institute of Cancer Research, London, UK



Commercial workshop: Advances in hepatocellular carcinoma

Sponsored by Bayer Schering Pharma

13:00 - 14:00

Hosted by Jeffrey Evans

Centre for Oncology and Applied Pharmacology, University of Glasgow, UK

- **Tim Meyer**
Royal Free Hospital, London, UK
Future treatments of hepatocellular cancer
- **Speaker to be confirmed**
Epidemiology staging and prognosis of hepatocellular cancer
- **Speaker to be confirmed**
The management of hepatocellular cancer



Commercial workshop: Cancer DSA™ - a platform for discovery in oncogenomics

Sponsored by Almac Diagnostics

13:00 - 14:00

Hosted by Patrick Johnston

School of Biomedical Sciences, Queens University, Belfast, UK

- **Karl Mulligan**
Almac Diagnostics, Craigavon, Northern Ireland, UK
Deciphering the transcriptome: rationale for development and technical overview of the Cancer DSA™ range of research tools and their applications in basic, pre-clinical and clinical research
- **Paul Mullan**
School of Biomedical Sciences, Queens University, Belfast, UK
Identification of the novel functions of the proto-oncogene TBX2 that is over-expressed in 15-20% of breast cancer cases
- **Lisa Baumbach-Reardon**
Dr John T MacDonald Foundation Centre for Medical Genetics, University of Miami, USA
Multi-ethnic comparisons of genomic signatures in breast cancer using the Breast Cancer DSA™ research tool



Careers workshop for research nurses involved in clinical trials

14.00 – 15.00

Hosted by Anne Croudass

University of Southampton, UK

Clinical fellows' careers workshop

14.00 – 15.00

Hosted by Simon Vincent

Cancer Research UK, London, UK

- **Kiki Thahtis**
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK



Does pancreatic cancer get the attention it deserves? How can we improve survival rates in pancreatic cancer?

Sponsored by Pancreatic Cancer UK

14.00 – 15.00

Hosted by Sue Ballard

Pancreatic Cancer UK

Co-chaired by John Neoptolemos¹, Pippa Corrie² and Steve Pereira³

¹University of Liverpool, UK; ²Addenbrooke's Hospital and University of Cambridge, UK; ³Pancreatic Society, BSG and University College London Hospital, UK

- **Les Niewiara**
Pancreatic Cancer UK
Cancer of the what? Striving for survival – the patient view
- **Nick Lemoine**
Institute of Cancer and CR-UK Clinical Centre, University of London, UK
Can the pancreas learn from other cancers or should they be learning from the pancreas? Can the pancreas achieve as high a profile as the breast?
- **Ross Carter**
Pancreatic Society and Glasgow Royal Infirmary, UK
The view from the coal-face: can we make it a properly equipped front-line?
- **Sue Ballard**
Pancreatic Cancer UK
Final comment

Post doc's careers workshop

14.00 – 15.00

- **Sarah Loddick**
AstraZeneca, UK
- **Peter Burdon**
Novartis, UK
- **Richard Kennedy**
Almac Diagnostics, UK
- **Isobel Greenfield**
Roche, UK

BACR Prize Lectures: BACR/AstraZeneca Young Scientist Frank Rose Award and BACR Translational Research Award

14.00 – 15.00

Hosted by Robert Brown

Chairman of the BACR, UK

- **Owen Sansom**
Beatson Institute for Cancer Research, Glasgow, UK
C-myc deficiency rescues APC deficiency, prevents Wnt dependent intestinal regeneration and is required for the DNA damage response *in vivo*
- **Jorge Reis-Filho**



Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
Basal-like carcinomas: from pathology to mouse-models and beyond

Tuesday 2 October 2007

BACR educational workshop: Therapeutic approaches to targeting tumour apoptosis - How basic pathway analysis has led to new drugs

08.00 – 08.50

Hosted by Caroline Dive

Paterson Institute for Cancer Research, University of Manchester, UK

- **Sarah Holt**
Paterson Institute for Cancer Research, University of Manchester, UK
Understanding the regulation of apoptosis
- **Caroline Dive**
Paterson Institute for Cancer Research, University of Manchester, UK
Therapeutic attack on apoptosis pathways



BOA educational workshop: Clinical role of advanced technology in radiation therapy

08.00 – 08.50

Hosted by Christopher Nutting

Royal Marsden Hospital and The Institute of Cancer Research, London, UK

- **Christopher Nutting**
Royal Marsden Hospital and The Institute of Cancer Research, London, UK
Advances in technology in radiation therapy
- **Ranald MacKay**
Christie Hospital, Manchester, UK
The impact of image guidance in radiotherapy



Commercial workshop: Integrated microarray based approaches to cancer genomics

Sponsored by Affymetrix

13.00 – 14.00

Hosted by Ruby Gadelrab

Marketing Programs, Affymetrix

- **Pim French**
Erasmus MC, Rotterdam, The Netherlands
Identification of molecular subgroups and genetic aberrations in glial brain tumours
- **Geoff Scopes**
Affymetrix, UK



Integrated approaches in cancer research - Increasing the value of a cancer genome study

Commercial workshop: Delivering tomorrow's cancer drugs: Sanofi-Aventis oncology pipeline and late stage trials

Sponsored by Sanofi-Aventis

13.00 – 14.00

Hosted by Isabelle Tabah-Fiche

Global Oncology Franchise, Sanofi-Aventis, UK

- **Isabelle Tabah-Fiche**

Global Oncology Franchise, Sanofi-Aventis, UK

Delivering tomorrow's cancer drugs: Sanofi-Aventis oncology pipeline



How to publish your results

Sponsored by the British Journal of Cancer

14.00 – 15.00

Hosted by Nicola McCarthy

Nature Reviews Cancer, UK



Designing a clinical trial - from inspirational idea to grant application

14.00 – 15.00

Hosted by Judith Bliss

The Institute of Cancer Research, Sutton, UK

- **Andrew Tutt**

Breakthrough Research Centre, London, and Guy's, Kings and St Thomas' Cancer Centre, London, UK

- **Lindsay Johnson**

The Institute of Cancer Research, Sutton, UK

- **Jo Haviland**

The Institute of Cancer Research, Sutton, UK

PhD students' careers workshop: how to find a post doc position

14.00 – 15.00

Hosted by Sally Leever

CR-UK London Research Institute, UK

- **Sheila Bingham**

MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, University of Cambridge, UK

- **Carl-Henrik Heldin**

Ludwig Institute for Cancer Research, Uppsala University, Sweden

- **Tony Kouzarides**

Wellcome Trust/CR-UK Gurdon Institute, University of Cambridge, UK

Women in science workshop – Addressing the problems

14.00 – 15.00

Hosted by Clare Isacke

Breakthrough Breast Cancer Research Centre, UK

- **Rebecca Smith**
Biochemical Society, UK

Wednesday 3 October 2007

Commercial workshop: Epigenetics and regulatory analysis in the cancer genome: applications of Chromatin IP (ChIP) and MeDIP

Sponsored by Affymetrix

13.00 – 17.00

Hosted by Geoff Scopes

Affymetrix Ltd, UK

- **Geoff Scopes**
Affymetrix Ltd, UK
Welcome and introduction
- **Jason Carroll**
CR-UK Cambridge Research Institute, UK
Whole genome oestrogen receptor binding
- **Jason Carroll, Alex Watkins and Geoff Scopes**
CR-UK Cambridge Research Institute and Affymetrix Ltd, UK
Panel-led interactive discussion session: considerations for ChIP-on-chip experimental design
- **Alex Watkins**
Affymetrix Ltd, UK
Data analysis session introduction: TAS and IGB
- **Speaker to be announced**
Affymetrix Ltd, UK
Genome Suite from Partek for ChIP-on-chip analysis
- **Martin Seifert**
Genomatix, UK
Genomatix ChIPInspector
- **Geoff Scopes**
Affymetrix Ltd, UK
Discussion - Data analysis and other questions

